EU launches nano-pharmaceutical project: Phoenix
An innovation project that aims to create an “Open Innovation Test Bed”
A part of the EU’s Horizon2020 Framework Programme an innovation project that aims to create an “Open Innovation Test Bed” for nano-pharmaceuticals – “Phoenix” – was launched on 1 March 2021. This cross-European project is coordinated by the Luxembourg Institute of Science and Technology (LIST) and consists of 11 partners from academia and industry across Europe.
Nano-pharmaceuticals have the potential to drive scientific and technological development in Europe and offer great clinical and socio-economic benefits to society, industry, and patients. Yet, due to the lack of resources, the production of innovative nano-pharmaceuticals is challenging for many players in the EU nanomedicine market. Phoenix is designed to enable seamless, timely, and cost-friendly transfer of nano-pharmaceuticals from lab bench to clinical trials by providing the Phoenix-Open Innovation Test Bed (OITB).
This “test bed” will offer a consolidated network of facilities, technologies, services, and expertise for all the technology transfer aspects from characterisation, testing, verification up to scale-up. In addition, it will develop and establish new facilities and upgrade existing ones to take them available to small- and medium-sized enterprises, start-ups, and research labourites for scale up. In doing so, the project aims to generate new services that are open to the public so the quality of nano-pharmaceuticals can improve.
Curious to learn more? Read more about the project.
Looking for more (open) data related news and events? Visit the EDP news archive and events calendar and follow us on Twitter, Facebook or LinkedIn.